미국 식품의약국 미승인 두타스테라이드의 국내 남성형 탈모증 약물요법 적용에 대한 후향적 평가
Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Androgenetic alopecia (AGA), one of alopecias, requires continuous treatment in order to prevent or stop it, and patient’s compliance is very important. Currently, only two drugs (finasteride, minoxidil) have been approved for AGA by Food and Drug Administration of United States (US FDA). However, another α-2 reductase inhibitor, dutasteride, is approved by Korea Ministry of Food and Drug Safety (MFDS) through a phase III trial. For treatment, pharmacotherapy of AGA usually combines topical minoxidil 7% with one of oral α-2 reductase inhibitor. Objectives: We evaluated the comparative efficacy and adverse effect between topical minoxidil 7%/finasteride 1 mg and topical minoxidil 7%/dutasteride 0.5 mg pharmacotherapy for outpatients with AGA. Also we evaluated the relationship between therapeutic effect and regular hospital visit. Method: This study was performed retrospectively based on electronic medical record (EMR) data of total 98 patients (topical minoxidil 7% with dutasteride 0.5 mg (Avodart®) or finasteride 1 mg (Alopecia®, Propecia®) with diagnosis of AGA from department of dermatology at a secondary hospital from January 1st, to May 31st, 2014. Results: The efficacy and adverse event of topical minoxidil 7%/dutasteride 0.5 mg (DUTA group) were 100% and 45.7%, and of topical minoxidil 7%/finasteride 1 mg (FINA group) were 92.1% and 33.3%, respectively. The mean onset time of responses and adverse events in the FINA group were 3.86 months and 4.43 months. Those in the DUTA group were 3.97 months and 5.06 months. Conclusion: Both FINA and DUTA group were highly effective, but the DUTA group showed higher efficacy and adverse effects than those in the FINA group. Dutasteride may be another alternative in AGA treatment
Abstract
Background: Androgenetic alopecia (AGA), one of alopecias, requires continuous treatment in order to prevent or stop it, and patient’s compliance is very important. Currently, only two drugs (finasteride, minoxidil) have been approved for AGA by Food and Drug Administration of United States (US FDA). However, another α-2 reductase inhibitor, dutasteride, is approved by Korea Ministry of Food and Drug Safety (MFDS) through a phase III trial. For treatment, pharmacotherapy of AGA usually combines topical minoxidil 7% with one of oral α-2 reductase inhibitor. Objectives: We evaluated the comparative efficacy and adverse effect between topical minoxidil 7%/finasteride 1 mg and topical minoxidil 7%/dutasteride 0.5 mg pharmacotherapy for outpatients with AGA. Also we evaluated the relationship between therapeutic effect and regular hospital visit. Method: This study was performed retrospectively based on electronic medical record (EMR) data of total 98 patients (topical minoxidil 7% with dutasteride 0.5 mg (Avodart®) or finasteride 1 mg (Alopecia®, Propecia®) with diagnosis of AGA from department of dermatology at a secondary hospital from January 1st, to May 31st, 2014. Results: The efficacy and adverse event of topical minoxidil 7%/dutasteride 0.5 mg (DUTA group) were 100% and 45.7%, and of topical minoxidil 7%/finasteride 1 mg (FINA group) were 92.1% and 33.3%, respectively. The mean onset time of responses and adverse events in the FINA group were 3.86 months and 4.43 months. Those in the DUTA group were 3.97 months and 5.06 months. Conclusion: Both FINA and DUTA group were highly effective, but the DUTA group showed higher efficacy and adverse effects than those in the FINA group. Dutasteride may be another alternative in AGA treatment
참고문헌 (25)
- 최광성, "한국인의 두피모발 특성과 남성형탈모증", 대한의사협회지, 56(1), pp.45~54 (2013), 대한의사협회
- "Press release: Androgenetic alopecia patients steadily increased by 4.8% year Health Insurance Review & Assessment"[URL]
- KIMS, "KIMS book in book pharmacy guide" (2014), KIMS Co
- Cash TF, "Attitudes, behaviors, and expectations of men seeking medical treatment for male pattern hair loss : results of a multinational survey", Curr Med Res Opin, 25(7), pp.1811~1820 (2009)
- Lee WS, "Updates of Alopecia", Drug information, 38(4) (2012)
- "National health Information Portal"[URL]
- Hoffmann R, "Steroidogenic isoenzymes in human hair and their potential role in adnrogenetic alopecia", Dermatology, 206(2), pp.85~95 (2003)
- Eun HC., "Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study", J Am Acad Dermatol, 63(2), pp.252~258 (2010)
- "A Long-term Study to determine safety and efficacy of dutasteride in male subjects with Androgenetic alopecia"[URL]
- Olsen EA., "The importance of dual 5- alpha reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride vs. finasteride", J Am Acad Dermatol, 55, pp.1014~1023 (2006)
- Rogers NE, "medical treatments for male and female pattern hair loss", J Am Acad Dermatol, 59(4), pp.547~566 (2008)
- Gubelin HW., "A randomized, active-and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia", J Am Acad Dermatol, 70(3), pp.489~498 (2014)
- "Druginfo/www.druginfo.co.kr.URL="[URL]
- "Age’ emerged as the new variable on competition of treatment for alopecia, MSD-GSK/www.docdocdoc.co.kr.URL="[URL]
- Roehrborn CG., "Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia", Urology, 63(4), pp.709~715 (2004)
- Clark RV., "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual5alpha-reductase inhibitor", J Clin Endocrinol Metab, 89(5), pp.2179~2184 (2004)
- Dallob AL., "The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness", J Clin Endocrinol Metab, 79(3), pp.703~706 (1994)
- Jung JY., "Effect of dutasteride 0.5 mg", d in men with androgenetic alopecia recalcitrant to finasteride, 2014, pp.53(11), 1351~1357
- "Druginfo/www.druginfo.co.kr.URL="[URL]
- Tsai JC., "Effect of minoxidil concentration on the deposition of drug and vehicle into the skin", Int J Pharm, 96, pp.111~117 (1993)
- Olsen EA., "A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men", J Am Acad Dermatol, 57(5), pp.767~774 (2007)
- Irwig MS., "Persistent sexual side effects of finasteride for male pattern hair loss", J Sex med, 8(6), pp.1747~1753 (2011)
- Yim E., "5α-Reductase inhibitors in androgenetic alopecia", Curr Opin Endocrinol Diabetes Obes, 21(6), pp.493~498 (2014)
- "Drug safety and Availability; Questions and Answers: Finasteride label changes"[URL]